Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00036270 |
To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast cancer.
This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries. This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined. A pre-specified analysis of the pooled data will be conducted.
Condition | Intervention | Phase |
---|---|---|
Breast Neoplasms |
Drug: exemestane (Aromasin) Drug: tamoxifen + exemestane |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Randomized Phase III Study of Exemestane (Aromasin) for 5 Years Versus Tamoxifen for 2.5- 3 Years Followed by Exemestane (Aromasin) for a Total of 5 Years as Adjuvant Therapy for Postmenopausal, Receptor Positive, Node Negative or Node Positive Breast Cancer Patients |
Estimated Enrollment: | 2400 |
Study Start Date: | October 2001 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
exemestane: Experimental |
Drug: exemestane (Aromasin)
exemestane, orally, 25 mg, for 5 years
|
tamoxifen + exemestane: Experimental |
Drug: tamoxifen + exemestane
tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy
|
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Pfizer Inc ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | 971-ONC-0028-081, A5991012 |
Study First Received: | May 8, 2002 |
Last Updated: | December 17, 2008 |
ClinicalTrials.gov Identifier: | NCT00036270 |
Health Authority: | United States: Food and Drug Administration |
Skin Diseases Breast Neoplasms Exemestane Tamoxifen Breast Diseases |
Estrogen Antagonists Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Hormonal Antineoplastic Agents Hormone Antagonists Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Enzyme Inhibitors |
Bone Density Conservation Agents Selective Estrogen Receptor Modulators Pharmacologic Actions Estrogen Receptor Modulators Neoplasms Neoplasms by Site Therapeutic Uses Aromatase Inhibitors |